• 主页
  • 查找结果
  • ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts.

ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts.

Human pathology (2014-04-29)
Kimberly C Wiegand, Keiyan Sy, Steve E Kalloger, Hector Li-Chang, Ryan Woods, Aalok Kumar, Catherine J Streutker, Sara Hafezi-Bakhtiari, Chen Zhou, Howard J Lim, David G Huntsman, Blaise Clarke, David F Schaeffer
摘要

ARID1A/BAF250a has been recently implicated as a tumor suppressor in gastric cancer. We sought to clarify the clinical significance of BAF250a/ARID1A in relation to other clinical parameters and relevant biomarkers in gastric carcinoma. Cases from 2 separate cohorts of patients with gastric carcinoma from Vancouver (n = 173) and Toronto (n = 80) were selected for the construction of tissue microarrays, which were used to assess the immunohistochemical status of BAF250a (anti-ARID1A), mismatch repair proteins and p53, as well as in situ hybridization for HER2 amplification and Epstein-Barr virus infection. The Toronto cohort contained a higher proportion of early stage cases (P = .019) and a smaller proportion of cases from the proximal stomach (P < .001). Overall, immunohistochemical loss of BAF250a was observed in 22.5% of gastric adenocarcinomas from the Vancouver group and 20% from Toronto. In both cohorts, loss of BAF250a was positively associated with loss of mismatch repair protein expression (P < .0001 and P = .035, respectively). Loss of BAF250a expression was independently associated with poor overall survival in the Toronto cohort (P = .0015), whereas no significant association with survival was observed in the Vancouver cohort. BAF250a loss was not significantly associated with any additional clinical parameters in either cohort. HER2 amplification was confirmed as a negative prognostic factor in both cohorts. These findings suggest that ARID1A/BAF250a may be of prognostic significance in a subset of patients with early stage gastric cancer and that pathological assessment should increasingly use a multimarker approach.

材料
货号
品牌
产品描述

Sigma-Aldrich
Monoclonal Anti-MLH1 antibody produced in mouse, clone M1, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-MSH2 antibody produced in mouse, clone 4B2, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-MLH1 (N-terminal) 兔抗, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Rabbit anti-MSH2 Antibody, Affinity Purified, Powered by Bethyl Laboratories, Inc.

社交媒体

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

科研、开发、生产。

作为生命科学行业的全球领先供应商,我们致力于为科研、生物技术开发和生产,以及制药药物疗法开发和生产提供各类解决方案和服务。

© 2021年版权归德国达姆施塔特默克集团(Merck KGaA)及/或其附属公司所有。版权所有。

未经许可,严禁复制本网站上的任何资料。